StockData

MindWalk vs ProQR Therapeutics

HYFT and PRQR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How HYFT and PRQR compare

MindWalk grew revenue faster over the last twelve months (43.4% versus 11.4% for ProQR Therapeutics).

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricHYFTPRQR
Size and price
Share price$0.907$1.15
Change, 1 year−46.0%−47.0%
Change, 5 years−85.9%−84.0%
Beta (5Y)2.492.58
Employees–59
StockData Score
Total score77
Valuation score00
Growth score22
Performance score02 (better)
Health score5 (better)3
Dividend score00
Growth
Revenue growth (TTM)43.4% (better)11.4%
Revenue growth, 5Y average−2.8%–
Profitability
Gross margin60.8%–
Operating margin–−233%
Net margin–−229%
FCF margin−76.9% (better)−273%
Return on equity–−57.4%
Financial health
Debt / equity–0.06
Current ratio1.843.49 (better)
Piotroski F-score–1
Ownership
Held by institutions9.3%57.6%
Held by insiders0.00%37.8%
Insider net buying, 12 months–$1.3M

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.